India’s CDMO Sector Poised for Growth as Pharma Diversifies Beyond China
The global pharmaceutical landscape is undergoing a structural realignment as multinational drugmakers seek to reduce their reliance on Chinese manufacturing. Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this "China Plus One" strategy, positioning themselves as trusted, high-quality alternatives for global innovators.
The Strategic Shift Away from China
The transition toward Indian CDMOs is not merely a reaction to recent regulatory scrutiny surrounding Chinese giants like WuXi AppTec; it is a trend that has been gaining momentum for over two years. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies began diversifying their supply chains well before recent geopolitical and regulatory shifts.
The inclusion of certain entities in regulatory watchlists has further accelerated this movement, providing clarity for global pharma to decouple from Chinese dependencies. As a result, Indian players are aggressively scaling up capacity and increasing capital expenditure (capex) to meet the rising global demand.
Sai Life Sciences: Scaling Capacity and Revenue Mix
Sai Life Sciences is actively capitalizing on this momentum. The company has announced a significant expansion plan, intending to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This investment will be funded through a combination of internal accruals and debt, ensuring a stable balance sheet.
A key indicator of this shifting landscape is the company's revenue composition. Over the last four years, the contribution from global "Big Pharma" companies has nearly doubled, rising from 28% to 49%. This shift underscores a deeper integration of Indian manufacturers into the long-term value chains of the world's largest drugmakers.
From Clinical Supplies to Commercial Manufacturing
One of the most significant developments in the Indian CDMO space is the evolution of the services provided. Historically, global pharmaceutical companies utilized India primarily for clinical-stage supplies. However, there is a visible trend toward utilizing Indian facilities for large-scale commercial manufacturing.
Sai Life Sciences has noted a substantial increase in its late-stage development pipeline. The number of molecules in the Phase III and pre-registration stages has grown from six to eleven, reflecting increased confidence from global innovators. While the regulatory nature of pharmaceutical manufacturing means that moving production lines takes time, the long-term pipeline suggests a permanent shift in how global pharma views India.
Outlook for the Indian CDMO Industry
Despite the long lead times required for regulatory approvals and product transfers, the outlook for the sector remains robust. Sai Life Sciences has maintained its revenue growth guidance of 15-20% CAGR. While the immediate quarterly impact may be tempered by the time required for capacity utilization, the structural opportunity for Indian CDMOs to grow "bigger and better" is evident.
Key Takeaways
- Diversification Trend: Global pharma is actively moving away from China, viewing India as the most viable alternative for manufacturing diversification.
- Shift in Service Scope: Indian CDMOs are transitioning from providing clinical-stage supplies to handling large-scale, commercial-grade manufacturing.
- Aggressive Expansion: Major players like Sai Life Sciences are committing significant capital (up to ₹1,300 crore) to expand capacity to meet the rising demand from top-tier global pharma companies.